12 / 17
Page 63
allied
academies
August 14-16, 2017 | Toronto, Canada
BRAIN DISORDERS AND DEMENTIA CARE
4
th
International Conference on
Neurosurg, an open access journal
ISSN: 2471-9633
Blocking the LINGO-1 pathway as a novel therapeutic approach for CNS remyelination and repair:
From discovery to clinical trials
Sha Mi
Biogen, USA
L
INGO-1 is a leucine rich repeat, Ig domain containing,
Nogo receptor interactive protein that is selectively
expressed in CNS oligodendrocytes and neurons. Its
expression is developmentally regulated, as well as up-
regulated in CNS diseases and spinal cord injury. LINGO-1
negatively regulates oligodendrocyte differentiation and
myelination, neuronal survival and axonal regeneration
by activating RhoA and inhibiting ATK phosphorylation.
Opicinumab (anti-LINGO-1) is the first anti-LINGO-1 antibody
to enter clinical development for CNS repair. The Phase I
study found anti-LINGO-1 to be safe and well tolerated up
to the maximum planned dose of 100 mg/kg. In the Phase
II Renew trial, compared with placebo, participants treated
with opicinumab showed improved optic nerve conduction
latency (measured by full-field visual evoked potential), and
indicative of remyelination. In the phase 2b SYNERGY (active
relapsing MS trial), an inverted U-shaped dose response was
seen in SYNERGY suggesting a clinical effect of opicinumab.
e:
sha.mi@biogen.comNeurosurg 2017, 2:2
DOI: 10.21767/2471-9633-C1-006